Repligen Reports First Quarter 2015 Financial Results -

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Repligen Reports First Quarter 2015 Financial Results

- Product Sales Increase 45% to a Record $20.8 Million - - Conference Call and Webcast Today at 8:30 a.m. EDT -

WALTHAM, Mass., May 7, 2015 (GLOBE NEWSWIRE) -- Repligen Corporation (Nasdaq: RGEN ) today reported financial results for the first quarter ended March 31, 2015. Below are the Company’s performance highlights for the quarter, followed by updated financial guidance for the year 2015 and access information for today’s webcast and conference call.

First Quarter Financial Highlights  

  • Bioprocessing product revenue for the first quarter of 2015 was $20.8 million, compared to $14.3 million for the first quarter of 2014, an increase of 45% including a negative impact of 12% from foreign currency translation. Total revenue for the first quarter of 2015 was comprised entirely of bioprocessing product revenue, while during the first quarter of 2014, total revenue of $16.3 million included a one-time upfront payment of $2.0 million from BioMarin Pharmaceutical Inc. under our therapeutic asset purchase agreement announced in January 2014.  
  • Gross margin reached 61.2% for the first quarter of 2015, compared to 55.8% for the first quarter of 2014. Product gross profit for the first quarter of 2015 was $12.7 million, compared to product gross profit of $8.0 million for the first quarter of 2014, an increase of 59%.  
  • Operating income for the first quarter of 2015 was $4.0 million, or 19.4% of product revenue. Operating income for the first quarter was impacted by the recognition of $1.1 million in contingent consideration expense based on the high probability of the Company achieving a 2015 sales milestone for the Alternating Tangential Flow (ATF) System, as predefined in the Company’s asset purchase agreement with Refine Technology, LLC. Operating income was $5.3 million for the first quarter of 2014, which included the aforementioned non-product related payment of $2.0 million.  
  • Net income for the first quarter of 2015 was $2.9 million, or $0.09 per diluted share, including the aforementioned $1.1 million contingent consideration expense. This compares with net income of $4.3 million for the first quarter of 2014, including the aforementioned non-product related revenue of $2.0 million.  
  • EBITDA (Non-GAAP) 1  was $5.3 million for the first quarter of 2015, including the aforementioned $1.1 million contingent consideration expense. This compares to EBITDA of $6.2 million during the first quarter of 2014, which included the aforementioned non-product related payment of $2.0 million.

1  See Reconciliation of GAAP Net Income to Non-GAAP EBITDA chart at the end of this release

Operating expenses for the three-month period ended March 31, 2015 were $16.8 million compared to $11.0 million for the same period in 2014, an increase of $5.8 million. The increase in operating expense included a $1.7 million increase in cost of product revenue associated with higher product sales, $1.1 million in contingent consideration expense based on the high probability of achieving a 2015 sales milestone for the ATF System and a $2.6 million increase in sales, general and administrative (SG&A) expense. The increase in SG&A expense is due primarily to costs related to the expansion of staff and facilities and a $1.2 million increase related to professional fees and systems implementation to support the integration of the ATF System, which Repligen acquired from Refine Technology, LLC in June 2014.

Tony J. Hunt, Chief Operating Officer and designated President and CEO of Repligen said, “2015 is off to a strong start, with first quarter revenue gains across all of our product groups and particular strength in our affinity ligand and growth factor businesses. Our gross margin expansion was driven by increased capacity utilization in our plants. As anticipated, we launched our OPUS® 60 cm diameter pre-packed chromatography columns at the end of March, and we have two additional product launches planned for this year. With a larger commercial organization now in place, we are focused on expanding our customer base, building our brand and increasing the market penetration of our proprietary products.”

Walter C. Herlihy, retiring President and Chief Executive Officer said, “Our first quarter results are indicative of the Company’s potential to deliver strong organic growth and achieve outstanding operating performance in the Life Sciences sector. I am confident that the combination of sustained investment in new product development and additional strategic acquisitions will enable Repligen to continue to deliver value for our customers and our shareholders.”

Financial Guidance for 2015 Based on our first quarter results and expectations for the remainder of 2015, we are revising our financial guidance as summarized below. This guidance for the year 2015 is based on expectations for our existing business and does not include the impact on our revenue and expenses of potential milestone payments from BioMarin, the financial impact of potential bioprocessing acquisitions or future fluctuations in foreign currency exchange rates. 

  • Revenue guidance for the year 2015 is $75-$78 million, an increase from our previous guidance of $72-$75 million. Our revenue projection for 2015 is comprised exclusively of bioprocessing product sales and reflects 24%-29% sales growth, an increase from our previous guidance of 19%-24% growth. This guidance includes an estimated negative adjustment to sales growth of approximately 8% to accommodate the impact of foreign currency translation at current exchange rates.
  • Product gross margin for the year 2015 is expected to be 56%-58%, an increase from our previous guidance of 55%-57%.
  • Operating expenses for the year 2015 are expected to be $62-$64 million, an increase from our previous guidance of $60-$62 million, due to increased cost of goods associated with higher expected product sales and an increase in projected R&D expense to $6-$7 million vs. prior guidance of $5-$6 million. Contingent consideration of approximately $1.5 million and SG&A expense of $21-$23 million are consistent with our previous guidance.
  • Total income from operations for the year 2015 is expected to be $14-$16 million, an increase from our previous guidance of $12-$14 million. Net income is expected to be $10-$12 million, an increase from our previous guidance of $8-$10 million.

First Quarter 2015 Business Highlights

  • In January, the Company announced that Tony J. Hunt, current Chief Operating Officer of Repligen, will succeed Walter C. Herlihy, Ph.D. as President and Chief Executive Officer upon Dr. Herlihy’s retirement on May 21, 2015 at the Company’s Annual Meeting of Stockholders. Dr. Herlihy will continue with Repligen in the capacity of Senior Advisor for the remainder of 2015.  
  • In February, the Company announced the completion of an 11,000 square foot expansion of its U.S. manufacturing facility, including dedicated areas for the production and assembly of the ATF System. The ATF System is a market-leading product line used to significantly increase cell density and product yield during the fermentation step of the biologic drug manufacturing process.  
  • In March, we formally launched our OPUS ® 60 cm diameter (OPUS 60) chromatography columns at Biopharmaceutical Development & Production Week 2015. OPUS 60 has the largest capacity among pre-packed chromatography columns, used by biopharmaceutical manufacturers to purify monoclonal antibodies and other biologic drugs. The addition of OPUS 60 further differentiates OPUS as the only pre-packed column line with the capacity to process harvests from 1,000 to 2,000 liter bioreactors, and Repligen as the only company to offer the flexibility of packing a wide array of resins to customized bed heights.

Conference Call   Repligen will host a conference call and webcast today, May 7, 2015 at 8:30 a.m. EDT, to discuss first quarter 2015 financial results and business updates. The live call can be accessed by dialing toll-free (844) 835-7432 for domestic callers or (404) 537-3372 for international callers. Dial-in participants must provide the passcode 34417361. In addition, a webcast will be accessible via the Investor Relations section of Repligen’s website www.repligen.com ; see Events & Presentations. Both the conference call and webcast will be archived for a period of time following the live event. The replay dial-in numbers are (855) 859-2056 for domestic callers and (404) 537-3406 for international callers. Replay listeners must provide the passcode 34417361.

Non-GAAP Financial Measures In this release, the Company is reporting earnings before interest, taxes, depreciation and amortization (EBITDA). EBITDA is a non-GAAP financial measure and should not be viewed as an alternative to GAAP measures of performance. The Company has provided a reconciliation of GAAP net income to EBITDA at the end of this release. The Company believes that the use of this non-GAAP measure better enables management and investors to benchmark its results against historical performance and the performance of peers, and to evaluate acquisition and other investment opportunities.

About Repligen Corporation Repligen Corporation (Nasdaq: RGEN ) is a life sciences company focused on the development and commercialization of high-value consumable products used in the process of manufacturing biological drugs. Our bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. We are the leading manufacturer of Protein A affinity ligands, a critical component of Protein A media that is used to separate and purify monoclonal antibody therapeutics. Our ATF System and our growth factor products are used to increase product yield during the fermentation stage of biologic drug manufacturing. In addition, we developed and market an innovative line of “ready-to-use” chromatography columns under our OPUS ® brand that we deliver pre-packed with our customers’ choice of purification media. Repligen’s corporate headquarters are in Waltham, MA (USA) and our manufacturing facilities are located in Waltham, MA and Lund, Sweden.

The following constitutes a “Safe Harbor” statement under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements, which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Investors are cautioned that statements in this press release which are not strictly historical statements, constitute forward-looking statements, including, without limitation, express or implied statements or guidance regarding future financial performance and position, including cash and investment position, the future demand for our bioprocessing products, objectives for future operations, our receipt of any future payments under the terms of our agreement with BioMarin, our contingent payment obligations under the terms of our agreement with Refine, plans and objectives for product development and acquisitions, our market share and product sales and other statements identified by words like “believe,” “expect,” “may,” “will,” “should,” “seek,” “anticipate,” or “could” and similar expressions. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with: our ability to successfully grow our bioprocessing business, including as a result of acquisition, commercialization or partnership opportunities; our ability to develop and commercialize products and the market acceptance of our products; reduced demand for our products that adversely impacts our future revenues, cash flows, results of operations and financial condition; the success of current and future collaborative or supply relationships, including our agreement with BioMarin; our ability to compete with larger, better financed bioprocessing, pharmaceutical and biotechnology companies; our ability to successfully integrate the ATF business; our ability to optimize manufacturing process; our compliance with all Food and Drug Administration and EMEA regulations; our volatile stock price; and other risks detailed in Repligen’s Annual Report on Form 10-K on file with the Securities and Exchange Commission and the other reports that Repligen periodically files with the Securities and Exchange Commission. Actual results may differ materially from those Repligen contemplated by these forward-looking statements. These forward looking statements reflect management’s current views and Repligen does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date hereof except as required by law.  

REPLIGEN CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(Unaudited)
         
   Three months ended March 31,  
    2015       2014    
Revenue:        
Product revenue $  20,816,276     $  14,334,687    
Royalty and other revenue    -        1,991,166    
Total revenue    20,816,276        16,325,853    
Operating expenses:        
Cost of product revenue    8,072,904        6,335,064    
Cost of royalty revenue    -        -    
Research and development    1,567,574        1,200,990    
Selling, general and administrative    6,024,526        3,383,610    
Contingent consideration - fair value adjustments    1,112,374        98,320    
Total operating expenses    16,777,378        11,017,984    
Income from operations    4,038,898        5,307,869    
Investment income    36,585        101,816    
Interest expense    (9,041 )      (14,085 )  
Other (expense) income    132,031        2,505    
Income before income taxes    4,198,473        5,398,105    
Income tax provision    1,268,986        1,121,002    
Net income $  2,929,487     $  4,277,103    
Earnings per share:        
Basic $  0.09     $  0.13    
Diluted $  0.09     $  0.13    
Weighted average shares outstanding:        
Basic    32,754,862        31,962,843    
Diluted    33,450,611        32,831,019    
Comprehensive income (loss) $  (936,491 )   $  4,136,134    
         
         
Balance Sheet Data: March 31, 2015   December 31, 2014  
Cash, cash equivalents and marketable securities* $  56,282,588     $  62,003,443    
Working capital    70,327,882        70,263,229    
Total assets    128,584,239        128,293,234    
Long-term obligations    3,468,166        5,879,013    
Accumulated deficit    (77,957,723 )      (80,887,208 )  
Stockholders' equity    111,932,015        111,731,808    
         
  *does not include restricted cash        
REPLIGEN CORPORATION
RECONCILIATION OF GAAP NET INCOME TO NON-GAAP EBITDA
         
         
    Three months ended March 31,
      2015       2014  
         
GAAP NET INCOME   2,929,487       4,277,103  
         
Non-GAAP Adjustments:      
  Investment Income   (36,585 )     (101,816 )
  Interest Expense   9,041       14,085  
  Tax Provision   1,268,986       1,121,002  
  Depreciation   749,098       637,286  
  Amortization   401,422       255,121  
         
NON-GAAP EBITDA   5,321,449       6,202,781  
         

Contact:  Sondra S. Newman Senior Director Investor Relations Repligen Corporation (781) 419-1881 snewman@repligen.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

DEFSEC Tackles Nasdaq Bid Price Hurdle with Share Move

Updated Category News Views 63

Navigating Bid Price Deficiency Issues Well, it seems DEFSEC Technologies Inc. found themselves in a tricky spot last week. A nasty gram from Nasdaq’s Listing Qualifications Department pointing out that DEFSEC's shares had dipped below that $1.00 per share requirement for too long—a full 30 business days. Now, don't panic just yet. This isn't about the shares getting...

Continue Reading
Unisys Opens Its 2027 Innovation Program Across India

Updated Category News Views 9

Talent pipelines rarely make the market’s pulse race, but they can expose whether a tech firm is still trying to build for the next turn. Unisys has opened registration for the 2027 Unisys Innovation Program, its eighteenth annual technical competition for engineering students in India. For a company selling cloud, AI, digital workplace, applications and enterprise...

Continue Reading
Snowhawk Enters Telarus as Digital Demand Gets Serious

Updated Category News Views 84

Telarus just pulled another serious capital partner into the room, and that matters more than the usual law-firm victory lap. Snowhawk Partners has invested in the technology services distributor alongside Columbia Capital, which remains a long-standing partner. Nobody disclosed a valuation, ownership percentage, financing mix, or closing date. Annoying? Sure. But the...

Continue Reading
ELEGOO's Formnext Push Tests a Broader 3D Ambition

Updated Category News Views 89

Frankfurt’s show floor is where product promises meet some very unforgiving eyeballs. ELEGOO arrived at Formnext 2026 with more than a refreshed machine or two: it is laying out a wider bet across resin printing, FDM printing, and 3D scanning. That matters because the company is no longer presenting itself as merely a supplier of affordable creator hardware. It wants to...

Continue Reading
Onward Therapeutics Secures $28M to Bolster Oncology R&D

Updated Category News Views 76

Cashing In to Conquer Cancer In the risk-laden world of biotech, Onward Therapeutics has just bagged a hefty NT$900 million—roughly US$28 million—from its Series B financing. That's not pocket change and speaks to the level of confidence their backers have, even as they plant their global headquarters firmly in Taipei since relocating from Switzerland. A Deep Dive...

Continue Reading
Stand Takes Colorado Bet on Wildfire-Smart Coverage

Updated Category News Views 119

Colorado’s insurance mess has finally attracted a company willing to price the driveway, the vents, and the tree line instead of shrugging at an entire ZIP code. Stand has launched homeowners coverage across the state, including mountain communities where wildfire exposure has made insurance both costly and scarce. This is not a small problem dressed up with a shiny...

Continue Reading
Trilith Holiday Tour Blends Film Access and Giving

Updated Category News Views 53

Snow machines, trolley rides, and a mental-health subsidy are sharing the same stage in Fayetteville this holiday season. That is an unusual mix, but it fits Trilith Foundation’s stated mission better than another generic lights-and-cocoa event ever could. From Nov. 21 through Dec. 31, the Foundation is turning its guided Trilith Studios tour into a seasonal experience...

Continue Reading
Abacus Global Faces Scrutiny Over Accounting Practices

Updated Category News Views 156

Storm Clouds Gather over Abacus Global Management If it ain't one thing, it's another—at least that's what folks holding the bag with Abacus Global (ABX) are thinking right now. News of a pending investigation has dropped like a lead balloon, and the air is thick with scrutiny over their financial dealings. We're jawing about related-party transactions now under the...

Continue Reading
Docusign Pushes Contract Data Into ChatGPT Sales Tools

Updated Category News Views 179

Contracts are where sales momentum goes to get lost, buried under old PDFs, approval chains, and somebody’s half-finished CRM note. Docusign’s November 17, 2026 launch is a sensible attempt to drag that information into the place sellers may increasingly spend their working day: ChatGPT for Sales. The company’s new plugin lets a sales rep pull agreement intelligence...

Continue Reading
SanMar’s Lott Tops Promo Products Power 50 Again in 2026

Updated Category News Views 132

Branded hoodies and logo tumblers rarely make Wall Street’s pulse race, but the numbers behind them deserve a hard look. Jeremy Lott, president and CEO of SanMar, was named the most influential leader in the U.S. promotional-products business for the second consecutive year, taking No. 1 in the 2026 Counselor Power 50 ranking. Awards can be fluff. A repeat win beside...

Continue Reading

Top 5 Most Recently Viewed Articles

Social Media Buzz Powers Hainan's Travel Boom

Updated Category News Views 205

Social Media Buzz Powers Hainan's Travel Boom This year marks a remarkable shift in Hainan's tourism, driven by the advent of visa-free travel access for international visitors. As the beautiful island in southern China opens its doors wider, a surge in travelers, especially travel bloggers from around the globe, is noticeable. Influencers from diverse backgrounds,...

Continue Reading
Kodiak Sciences Reports Q3 2025 Financial Milestones and Updates

Updated Category News Views 375

Kodiak Sciences Reports Q3 2025 Financial Milestones and Updates Kodiak Sciences Inc. (Nasdaq: KOD) has recently shared significant business highlights along with financial results for the third quarter of 2025. This biotechnology company is making strides in the field of retinal medicine. 'We are witnessing a period marked by sustained momentum,' expressed Victor...

Continue Reading
Vaisala Initiates Share Repurchase Program to Enhance Incentives

Updated Category News Views 193

Vaisala’s Strategy for Share Repurchases Vaisala Corporation is embarking on an important journey to repurchase its own shares as part of a broader incentive plan. This strategic decision follows the authorization granted by the Annual General Meeting, reflecting the company's commitment to fostering a rewarding environment for its employees. As a key player in climate...

Continue Reading
Investigating Customer Bancorp, Inc. Losses: Understand Your Rights

Updated Category News Views 92

Exploring Customers Bancorp, Inc.'s Recent Challenges Customers Bancorp, Inc., identified by the ticker CUBI, is dealing with significant accusations regarding the truthfulness of the business information it has shared with the public. The Rosen Law Firm, a respected advocate for investor rights, is currently looking into securities claims tied to these allegations. If...

Continue Reading
Allurity and Onevinn: Transforming Cybersecurity Together

Updated Category News Views 374

Allurity Expands its Cybersecurity Portfolio with Onevinn Acquisition Allurity, a prominent European provider of cybersecurity services, has exciting news to share. The company has taken a significant step forward by acquiring Onevinn, a Swedish company renowned for its intelligent security and managed services. This move not only showcases Allurity's ambitions but also...

Continue Reading